// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Attentional bias toward suicide-relevant information in suicide attempters: A cross-sectional study and a meta-analysis

S.Richard-Devantoy - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

WORKER PRODUCTIVITY LOSS REMAINS A MAJOR ISSUE FOR PATIENTS WITH INFLAMMATORY ARTHRITIS AND OSTEOARTHRITIS: RESULTS FROM THE INTERNATIONAL EULAR-PRO WORKER PRODUCTIVITY STUDY

S. Leggett - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).

Kyaw Lwin Aung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

GSK2256098

Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer.

Erica S Tsang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A sensitive biomarker panel to distinguish pancreaticobiliary malignancies from benign disease.

Atuhani S. Burnett - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool.

Shirley Xue Jiang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

Effect of cytoreductive surgery and HIPEC on survival in comparison to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.

Frederic Mercier - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.

Ivan Barrera - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Patient-level costs of treating metastatic gastric cancer by treatment strategy.

Yunni Jeong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns?

William Raskin - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Enrollment of esophago-gastric cancer patients in a clinical fast-track program and it’s affect on time to treatment and quality of life.

Atuhani S. Burnett - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC).

Winson Y. Cheung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The potential drug cost impact of nivolumab (N) in patients with advanced/metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) in Canada.

Kiran Virik - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).

Mayur Amonkar - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).

Lynn Huynh - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Lanreotide

Can recurrence patterns after curative resection for gastric adenocarcinoma (GCa) inform the selection of adjuvant treatment?

Shelly Luu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Method of diagnosis of pancreatic adenocarcinoma: A Nova Scotia experience.

Caitlin Lees - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).

Ian Chau - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).

Di Maria Jiang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

N/A

Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.

Lucy Xiaolu Ma - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Copyright © 2026. QuantiNova All rights reserved